共 86 条
- [1] Ajani JA(2019)Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 17 855-883
- [2] D’Amico TA(2016)Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 27 v57-1244
- [3] Bentrem DJ(2017)Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial JAMA Oncol 3 1237-10
- [4] Lordick F(1995)Oligometastases J Clin Oncol 13 8-111
- [5] Mariette C(2010)Oligometastases and oligo-recurrence: the new era of cancer therapy Jpn J Clin Oncol 40 107-249
- [6] Haustermans K(2024)Oligometastasis of Gastric Cancer: A Review Cancers 71 209-195
- [7] Al-Batran SE(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 243 189-224
- [8] Homann N(2006)Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma Ann Surg 29 2-2208
- [9] Pauligk C(2023)Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study Aug 25 212-1101
- [10] Hellman S(2024)Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial Lancet Oncol 402 2197-25